Eslicarbazepine Acetate Tablet
Product Images NDC 51407-782

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 51407-782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-779-30lb (Eslicarbazepine Acetate 200mg)

Label for Eslicarbazepine Acetate 200 mg oral tablets, supplied in a package of 30 tablets by Golden State Medical Supply, Inc. The label includes dosage strength, directions to take once daily, storage instructions, a barcode, and pharmacy dispensing information.*

FDA Label Image

51407-780-30lb (Eslicarbazepine Acetate 400mg)

Label for Eslicarbazepine Acetate Tablets, 400 mg strength, oral dosage form. The label indicates once daily dosing, contains 30 tablets per bottle, and is marketed by Golden State Medical Supply, Inc. Additional instructions include storage conditions and dispensing guidance.*

FDA Label Image

51407-781-60lb (Eslicarbazepine Acetate 600mg)

Label for Eslicarbazepine Acetate 600 mg oral tablets by Golden State Medical Supply, Inc. The label indicates the product is to be taken once daily, contains 60 tablets, and is prescription only. Storage instructions and dispensing information are also visible, along with NDC 51407-781-60.*

FDA Label Image

51407-782-30lb (Eslicarbazepine Acetate 800mg)

Label for Eslicarbazepine Acetate 800 mg oral tablets, packaged in a container of 30 tablets. The label indicates once daily dosing and is from Golden State Medical Supply, Inc. It includes storage instructions, usual dosage directions to see package insert, and a barcode with NDC 51407-782-30.*

FDA Label Image

Figure1.jpg (Figure1)

A chart showing fold change and 90% confidence intervals for eslicarbazepine acetate exposure by age, gender, hepatic, and renal impairment categories. The horizontal axis represents change relative to reference, with various points indicating fold changes and dosing recommendations summarized for each subgroup.*

FDA Label Image

Figure2.jpg (Figure2)

A forest plot chart showing fold change and 90% confidence intervals for eslicarbazepine acetate relative to reference when coadministered with various drugs. The chart lists carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproate, with notes recommending possible dose adjustments for carbamazepine, phenobarbital, and phenytoin, while others show no change.*

FDA Label Image

Figure3a.jpg (Figure3)

A chart showing the fold change and 90% confidence interval for various antiepileptic drugs (AEDs) including Carbamazepine, Gabapentin, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Topiramate, and Valproate, with corresponding recommendations on dose adjustments or monitoring. The horizontal axis is labeled 'Change of other drugs relative to reference.'*

FDA Label Image

Figure3b.jpg (Figure3b)

A forest plot chart displaying fold changes and 90% confidence intervals for various drugs relative to a reference, including Digoxin, Metformin, Simvastatin, Rosuvastatin, Ethinylestradiol, Levonorgestrel, and Warfarin (S- and R- forms). It includes recommendations adjacent to each drug regarding dose adjustments or monitoring requirements.*

FDA Label Image

Figure4.jpg (Figure4)

A Kaplan-Meier estimate chart showing the exit rate percentages with 95% confidence intervals for Eslicarbazepine Acetate tablets at 1200 mg and 1600 mg doses, comparing data from two studies and historical controls. The chart includes sample sizes for each data point and distinguishes between Study 1 and Study 2 results.*

FDA Label Image

Figure5.jpg (Figure5)

A bar chart comparing the proportion of patients by seizure frequency reduction from baseline (%) in groups receiving placebo, Eslicarbazepine Acetate 800 mg tablets, and Eslicarbazepine Acetate 1200 mg tablets. The x-axis shows ranges of reduction in seizure frequency, and the y-axis shows the proportion of patients as a percentage.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of the active ingredient Eslicarbazepine Acetate depicted as a molecular diagram showing its atomic arrangement and bonding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.